A case of hyperprogressive disease following atezolizumab therapy for pulmonary pleomorphic carcinoma with epidermal growth factor receptor mutation

A case of hyperprogressive disease following atezolizumab therapy for pulmonary pleomorphic carcinoma with epidermal growth factor receptor mutation

A 66-year old man with non-smoking history was diagnosed with pulmonary pleomorphic carcinoma of the right lower lobe. The carcinoma metastasized to the brain, lungs, pleura, and mediastinal lymph nodes. It was positive for epidermal growth factor receptor (EGFR) L858R mutation, and tumor cells high...

Full description

Bibliographic Details
Main Authors: Tomoyo Oguri, Shinji Sasada, Sachiko Seki, Saori Murata, Yumi Tsuchiya, Kota Ishioka, Saeko Takahashi, Reishi Seki, Shigemichi Hirose, Ryohei Katayama, Morio Nakamura
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:Respiratory Medicine Case Reports
Subjects:
Hyperprogressive disease (HPD)
Immune-related adverse events (irAE)
Immune-checkpoint inhibitor (ICI)
Epidermal growth factor receptor (EGFR) mutation
Pulmonary pleomorphic carcinoma
Online Access:http://www.sciencedirect.com/science/article/pii/S2213007121000678

Internet

http://www.sciencedirect.com/science/article/pii/S2213007121000678

Similar Items